Please login to the form below

Not currently logged in
Email:
Password:

Teva sues Apotex to block generic Coreg

Israel-headquartered Teva Pharmaceutical has sued Canada-based Apotex to prevent the generic rival from selling a copy of GlaxoSmithKline's (GSK) antihypertensive drug, Coreg (carvedilol).

Israel-headquartered Teva Pharmaceutical has sued Canada-based Apotex to prevent the generic rival from selling a copy of GlaxoSmithKline's (GSK) antihypertensive drug, Coreg (carvedilol).

Apotex, Teva and other generic-drug makers won FDA approval to sell the generic version on 5 September 2007. Teva says that it owns four patents which cover various forms and processes to make carvedilol.

To sell carvedilol, says Teva, Apotex might have to purchase the compound made using the patented process. Apotex has not supplied the necessary data required to rule whether the generic uses patented processes or not. Teva has filed for a court order to prevent patent infringement by Apotex.

For H1 FY07, Coreg posted sales of USD 854m and analysts say that the annual generic market for carvedilol could be worth as much as USD 50m.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...